Meta-Analysis
Copyright ©The Author(s) 2024.
World J Clin Cases. Mar 6, 2024; 12(7): 1272-1283
Published online Mar 6, 2024. doi: 10.12998/wjcc.v12.i7.1272
Table 1 The characteristics of included studies
Ref.

Age (yr)
Gender (M/F)
ASA (I/II)
BMI (kg/m2)
No. of patients
Ye et al[20], 2023Remimazolam68. 67 ± 4.5539/2544/64NM64
Propofol68. 67 ± 4.5536/2948/65NM65
Tan et al[21], 2021Remimazolam66.4 ± 4.819/1418/1522.7 ± 3.033
Propofol66.2 ± 5.021/1218/1523.2 ± 3.033
Hu et al[22], 2022Remimazolam70.11 ± 7.3769/10420/14422.75 ± 3.15173
Propofol69.92 ± 7.5772/10126/14022.73 ± 3.23173
Liu et al[23], 2023Remimazolam67.5 ± 4.951/5811/9623.7 ± 3.0107
Propofol67.5 ± 5.751/5610/9924.0 ± 2.6109
Guo et al[24], 2022Remimazolam70.4 ± 3.9 25/147/3223.0 ± 3.0 38
Propofol69.1 ± 4.0 22/167/3123.0 ± 3.4 38
Lu et al[25], 2022Remimazolam70.6 ± 4.778/1226/19222.2 ± 2.5200
Propofol70.1 ± 4.583/11717/18122.2 ± 2.3 200
Liu et al[26], 2021Remimazolam68.87 ± 2.58 54/6137/7825.35 ± 2.07 115
Propofol69.12 ± 2.7558/5946/7124.75 ± 2.16 117
Table 2 Significant features of each group
Ref.

No. of patients
Hypotension
Respiratory depression
Injection pain
Bradycardia
PONV
Dizziness
Successful sedation rate
Time to discharge
Time to total alert
Ye et al[20], 2023Remimazolam649107NM164NM9 ± 1.51
Propofol65473830NM365NM7.67 ± 2.27
Tan et al[21], 2021Remimazolam331NMNMNMNMNMNMNM3.82 ± 2.49
Propofol3316NMNMNMNMNMNMNM4.33 ± 2.97
Hu et al[22], 2022Remimazolam1735617131NM17219.92 ± 6.3415.09 ± 4.06
Propofol1738831830NM17319.55 ± 7.613.75 ± 4.22
Liu et al[23], 2023Remimazolam1073NMNM511439NMNM
Propofol10914NMNM674107NMNM
Guo et al[24], 2022Remimazolam38620NM101135NMNM
Propofol381795NM81436NMNM
Lu et al[25], 2022Remimazolam20073923NMNM200NM9.8 ± 3.7
Propofol200139202417NMNM200NM9.3 ± 3.7
Liu et al[26], 2021Remimazolam11515046103NM111NMNM
Propofol117120159101NM117NMNM